亚宝药业：ZY-A002获得药物临床试验批准通知书

Core Viewpoint - The company received approval from the National Medical Products Administration for the clinical trial of ZY-A002, which is aimed at treating cough variant asthma in children [1] Group 1: Product Information - ZY-A002 is indicated for dispelling wind and promoting lung function, as well as relieving spasms and cough [1] - The primary target condition for ZY-A002 is cough variant asthma in children, characterized by symptoms such as paroxysmal cough, throat itching, minimal or no phlegm, and clear nasal discharge [1] - The clinical symptoms associated with the condition include a pale tongue, thin white coating, and a wiry pulse [1]